Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market: Segmented by Brands (Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and Others), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America) - Growth, Trends, and Forecasts (2019 2028)
- Published Date: 2022-12-26
- Report ID: 138102
- Pages: 200
-
Format:
Report Overview
The global dipeptide peptidase 4 (DPP-4) market size stood at around USD 10.92 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Dipeptide peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. These inhibitors function by increasing incretin levels which in turn increases insulin secretion, thus decreasing blood glucose levels.
Market Drivers
Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period. Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.
1. Global DPP-4 Inhibitors Market Overview............................................
A. Market Size
2. Market Growth Drivers...
A. Growing geriatric population
B. Rise in cases of diabetes and obesity population
3. DPP-4 Inhibitors Market Segmentation................................................
A. By Brand
I. Januvia (Sitagliptin)
II. Onglyza/Kombiglyze (Saxagliptin)
III. Trajenta (Linagliptin)
IV. Nesina (Alogliptin)
V. Galvus (Vildagliptin)
VI. Other DPP-4
B. By Geography
I. North America Market Analysis
II. Europe Market Analysis
III. Asia-Pacific Market Analysis
IV. Middle-East and Africa Market Analysis
V. Latin America Market Analysis
4. DPP-4 Inhibitors Major Market Share.....
A. Market Analysis, Insights and Forecast
5. Competitive Landscape......
A. Major Players
B. Products in Pipeline
6. Key Company Profiles....
A. Merck Company overview, Product & Services, Strategies & Financials
B. AstraZeneca Company overview, Product & Services, Strategies & Financials
C. Eli Lilly Company, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape..
A. Policy changes and Reimbursement scenario
8. Factors Driving Future Growth..
A. Key Industry Developments
B. Mergers and Acquisitions
9. Potential Growth Opportunities.
A. Future Opportunities
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
